Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IrelandIPO:
25 May 2018Website:
http://www.iterumtx.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:44:59 GMTDividend
Analysts recommendations
Institutional Ownership
ITRM Latest News
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Executive Officer Judith Matthews - Chief Financial Officer Conference Call Participants Thomas Yip - HC Wainwright Jason Mccarthy - Maxim Group Operator Hello, everyone, and thank you for holding, and welcome to the Iterum Therapeutics Reports Third Quarter 2024 Financial Results. My name is Ezra [ph], and I will be your coordinator today.
- - ORLYNVAH TM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024.
Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Director & CEO Steven Aronin - SVP & Head, Clinical Development Conference Call Participants Operator Hello, everyone, and welcome to Iterum Therapeutics call to discuss the recent approval of ORLYNVAH the treatment of Uncomplicated UTIs. My name is Lydia, and I'll be your operator today.
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO , Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on deliveringdifferentiated anti-infectives aimed at combatting the global crisis of multi-drugresistant pathogens to significantly improve the lives of people affected byserious and life-threatening diseases around the world.
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America's IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024.
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced it will participate in the 2024 Maxim Healthcare Virtual Summit. Corey Fishman, CEO of Iterum, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 10:00 a.m. ET on October 16, 2024.
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2024 financial results before the open of the U.S. financial markets on Wednesday, August 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the subscription period of its previously announced rights offering (the “Rights Offering”) expired at 5:00 p.m., Eastern Time, on August 6, 2024. As previously disclosed, the Company distributed, at no charge, subscription rights to the Company's shareholders and holders of warrants that had contractual rights to participate in the Rights Offering which were not waived (each, an “eligible warrant holder” and collectively, the “eligible warrant holders”) as of 5:00 p.m., Eastern Time, on July 16, 2024 (the “Record Date”).
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the United States Patent and Trademark Office (USPTO) has issued a notice allowance for two U.S. patents and the Canadian Intellectual Property Office (CIPO) has issued a Canadian patent, all related to sulopenem etzadroxil and probenecid (oral sulopenem).
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women will be taken to Advisory Committee, and in its communication, highlighted that the purpose of the Advisory Committee was to discuss a) antimicrobial stewardship issues raised by potential approval and subsequent use of what would be the first oral penem in the U.S.; and b) the most appropriate target patient population(s) for treatment of uUTI with sulopenem etzadroxil/probenecid. The proposed date for the Advisory Committee meeting is September 9, 2024.
What type of business is Iterum Therapeutics?
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
What sector is Iterum Therapeutics in?
Iterum Therapeutics is in the Healthcare sector
What industry is Iterum Therapeutics in?
Iterum Therapeutics is in the Biotechnology industry
What country is Iterum Therapeutics from?
Iterum Therapeutics is headquartered in Ireland
When did Iterum Therapeutics go public?
Iterum Therapeutics initial public offering (IPO) was on 25 May 2018
What is Iterum Therapeutics website?
https://www.iterumtx.com
Is Iterum Therapeutics in the S&P 500?
No, Iterum Therapeutics is not included in the S&P 500 index
Is Iterum Therapeutics in the NASDAQ 100?
No, Iterum Therapeutics is not included in the NASDAQ 100 index
Is Iterum Therapeutics in the Dow Jones?
No, Iterum Therapeutics is not included in the Dow Jones index
When was Iterum Therapeutics the previous earnings report?
No data
When does Iterum Therapeutics earnings report?
The next expected earnings date for Iterum Therapeutics is 28 March 2025